215 related articles for article (PubMed ID: 19171674)
1. A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist.
Snider NT; Nast JA; Tesmer LA; Hollenberg PF
Mol Pharmacol; 2009 Apr; 75(4):965-72. PubMed ID: 19171674
[TBL] [Abstract][Full Text] [Related]
2. Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides.
Snider NT; Kornilov AM; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2007 May; 321(2):590-7. PubMed ID: 17272674
[TBL] [Abstract][Full Text] [Related]
3. Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6.
Sridar C; Snider NT; Hollenberg PF
Drug Metab Dispos; 2011 May; 39(5):782-8. PubMed ID: 21289075
[TBL] [Abstract][Full Text] [Related]
4. The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6.
Snider NT; Sikora MJ; Sridar C; Feuerstein TJ; Rae JM; Hollenberg PF
J Pharmacol Exp Ther; 2008 Nov; 327(2):538-45. PubMed ID: 18698000
[TBL] [Abstract][Full Text] [Related]
5. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
Priller J; Briley EM; Mansouri J; Devane WA; Mackie K; Felder CC
Mol Pharmacol; 1995 Aug; 48(2):288-92. PubMed ID: 7651362
[TBL] [Abstract][Full Text] [Related]
6. Effects of a commonly occurring genetic polymorphism of human CYP3A4 (I118V) on the metabolism of anandamide.
Pratt-Hyatt M; Zhang H; Snider NT; Hollenberg PF
Drug Metab Dispos; 2010 Nov; 38(11):2075-82. PubMed ID: 20702771
[TBL] [Abstract][Full Text] [Related]
7. Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.
Snider NT; Walker VJ; Hollenberg PF
Pharmacol Rev; 2010 Mar; 62(1):136-54. PubMed ID: 20133390
[TBL] [Abstract][Full Text] [Related]
8. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of Anandamide by Human Cytochrome P450 2J2 in the Reconstituted System and Human Intestinal Microsomes.
Walker VJ; Griffin AP; Hammar DK; Hollenberg PF
J Pharmacol Exp Ther; 2016 Jun; 357(3):537-44. PubMed ID: 27000802
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors.
Chen JK; Chen J; Imig JD; Wei S; Hachey DL; Guthi JS; Falck JR; Capdevila JH; Harris RC
J Biol Chem; 2008 Sep; 283(36):24514-24. PubMed ID: 18606824
[TBL] [Abstract][Full Text] [Related]
12. Expression and purification of orphan cytochrome P450 4X1 and oxidation of anandamide.
Stark K; Dostalek M; Guengerich FP
FEBS J; 2008 Jul; 275(14):3706-17. PubMed ID: 18549450
[TBL] [Abstract][Full Text] [Related]
13. Endogenous anandamide and cannabinoid receptor-2 contribute to electroacupuncture analgesia in rats.
Chen L; Zhang J; Li F; Qiu Y; Wang L; Li YH; Shi J; Pan HL; Li M
J Pain; 2009 Jul; 10(7):732-9. PubMed ID: 19409856
[TBL] [Abstract][Full Text] [Related]
14. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
Derocq JM; Bouaboula M; Marchand J; Rinaldi-Carmona M; Ségui M; Casellas P
FEBS Lett; 1998 Apr; 425(3):419-25. PubMed ID: 9563506
[TBL] [Abstract][Full Text] [Related]
15. Anandamide, Acting via CB2 Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures.
Malek N; Popiolek-Barczyk K; Mika J; Przewlocka B; Starowicz K
Neural Plast; 2015; 2015():130639. PubMed ID: 26090232
[TBL] [Abstract][Full Text] [Related]
16. Opposing roles of CB
Gobira PH; Oliveira AC; Gomes JS; da Silveira VT; Asth L; Bastos JR; Batista EM; Issy AC; Okine BN; de Oliveira AC; Ribeiro FM; Del Bel EA; Aguiar DC; Finn DP; Moreira FA
Br J Pharmacol; 2019 May; 176(10):1541-1551. PubMed ID: 30101419
[TBL] [Abstract][Full Text] [Related]
17. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
Golech SA; McCarron RM; Chen Y; Bembry J; Lenz F; Mechoulam R; Shohami E; Spatz M
Brain Res Mol Brain Res; 2004 Dec; 132(1):87-92. PubMed ID: 15548432
[TBL] [Abstract][Full Text] [Related]
18. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.
Shoemaker JL; Joseph BK; Ruckle MB; Mayeux PR; Prather PL
J Pharmacol Exp Ther; 2005 Aug; 314(2):868-75. PubMed ID: 15901805
[TBL] [Abstract][Full Text] [Related]
19. Anandamide induces cell death independently of cannabinoid receptors or vanilloid receptor 1: possible involvement of lipid rafts.
Sarker KP; Maruyama I
Cell Mol Life Sci; 2003 Jun; 60(6):1200-8. PubMed ID: 12861385
[TBL] [Abstract][Full Text] [Related]
20. Probable involvement of Ca(2+)-activated Cl(-) channels (CaCCs) in the activation of CB1 cannabinoid receptors.
Romero TR; Pacheco Dda F; Duarte ID
Life Sci; 2013 May; 92(14-16):815-20. PubMed ID: 23123446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
